Dr. Li received his MD from the University of Geneva School of Medicine, Switzerland, followed by postdoctoral training at the University of Texas Health Science Center San Antonio (UTHSCSA).  He is currently associate professor of Medicine at UTHSCSA. He previously created a series of myeloid/macrophage promoters (US patent issued) based on his early work on signal transduction, gene regulation, and promoter activity. Capitalizing on these promoters as well as state-of-the-art genetic engineering technology, his research current focuses on the development of hematopoietic stem cell-based macrophage-mediated gene therapies for Parkinson’s and various other diseases. Dr. Li aims to bring disease-modifying/neuroprotective treatment to Parkinson’s patients. He was the first prize winner of the UTHSCSA 2011 Technology Innovation in Novel Translation Program.